Molecular Genetics and Metabolism | VOL. 137
Read

Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II

Publication Date Sep 1, 2022

Abstract

Enzyme replacement therapy with weekly infused intravenous (IV) idursulfase is effective in treating somatic symptoms of mucopolysaccharidosis II (MPS II; Hunter syndrome). A formulation of idursulfase for intrathecal administration (idursulfase-IT) is under investigation for the treatment of neuronopathic MPS II. Here, we report 36-month data from the open-label extension (NCT02412787) of a phase 2/3, randomized, controlled study (HGT-HIT-094; NCT02055118) that assessed the safety and efficacy of monthly idursulfase-IT 10 mg in addition to weekly IV idursulfase on cognitive function in children older than 3 years with MPS II and mild-to-moderate cognitive impairment. Participants were also enrolled in this extension from a linked non-randomized sub-study of children younger than 3 years at the start of idursulfase-IT therapy. The extension safety population comprised 56 patients who received idursulfase-IT 10 mg once a month (or age-adjusted dose for sub-study patients) plus IV idursulfase (0.5 mg/kg) once a week. Idursulfase-IT was generally well tolerated over the cumulative treatment period of up to 36 months. Overall, 25.0% of patients had at least one adverse event (AE) related to idursulfase-IT; most treatment-emergent AEs were mild in severity. Of serious AEs (reported by 76.8% patients), none were considered related to idursulfase-IT treatment. There were no deaths or discontinuations owing to AEs. Secondary efficacy analyses (in patients younger than 6 years at phase 2/3 study baseline; n = 40) indicated a trend fo...

Concepts

General Conceptual Ability Scores General Conceptual Ability Least-squares Mean Secondary Efficacy Analyses Enzyme Replacement Adverse Event Treatment-emergent Adverse Event Hunter Syndrome Open-label Extension Treatment Of MPS

Round-ups are the summaries of handpicked papers around trending topics published every week. These would enable you to scan through a collection of papers and decide if the paper is relevant to you before actually investing time into reading it.

Coronavirus Research Articles published between Nov 28, 2022 to Dec 04, 2022

R DiscoveryDec 05, 2022
R DiscoveryArticles Included:  5

The coronavirus disease 2019 (COVID-19) is a contagious disease that is caused by a novel coronavirus. Bentham is offering subject-based scholarly con...

Read More

Climate change Research Articles published between Nov 28, 2022 to Dec 04, 2022

R DiscoveryDec 05, 2022
R DiscoveryArticles Included:  5

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cooki...

Read More

Quality Of Education Research Articles published between Nov 28, 2022 to Dec 04, 2022

R DiscoveryDec 05, 2022
R DiscoveryArticles Included:  4

Introduction: The Internet is an extensively used source of medical education by the public. YouTube is a valuable source of information which can be ...

Read More

Gender Equality Research Articles published between Nov 28, 2022 to Dec 04, 2022

R DiscoveryDec 05, 2022
R DiscoveryArticles Included:  3

Gender equity in the classroom is important for teachers to think about in order to ensure they are creating safe environments that allow their studen...

Read More

Coronavirus Pandemic

You can also read COVID related content on R COVID-19

R ProductsCOVID-19

ONE PROBLEM . ONE PURPOSE . ONE PLACE

Creating the world’s largest AI-driven & human-curated collection of research, news, expert recommendations and educational resources on COVID-19

COVID-19 Dashboard

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on “as is” basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The Copyright Law.